ISM 001
Alternative Names: ISM-001Latest Information Update: 21 Oct 2024
Price :
$50 *
At a glance
- Originator IsomAb
- Class Antibodies; Vascular disorder therapies
- Mechanism of Action Vascular endothelial growth factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Peripheral arterial disorders
Most Recent Events
- 15 Oct 2024 IsomAB plans a first-in-human trial for Peripheral arterial disorders
- 23 Feb 2024 Preclinical trials in Peripheral arterial disorders in United Kingdom (Parenteral) (Prior to February 2024)
- 20 Feb 2024 IsomAB plans to file Clinical Trials application (CTA) for peripheral arterial disorders